Avacta (AIM: AVCT) clears deferred bond repayments as AVA6103 milestones shape management options

Avacta Group plc (AIM: AVCT) has reduced the outstanding principal on its convertible bond to £12 million after paying an accelerated £2.613 million installment in cash, continuing a deliberate strategy of using recently raised equity to avoid potentially more dilutive share-based bond repayments. The September 4 payment comprised £2.4 million of principal plus associated interest and deferment fees and followed another accelerated repayment in July as well as the scheduled July installment, all settled in cash. The capital-structure progress came only days after Avacta granted 19.15 million new share options to its management team at an exercise price of 69 pence, equivalent to roughly 4.1% of the company’s existing issued share capital if all ultimately vest and are exercised. Chief executive Christina Coughlin received 13.4 million of those options, with half tied to clinical and pipeline milestones including AVA6103 data, another IND filing and selection of a next-generation clinical candidate. The juxtaposition creates a useful shareholder question: Avacta is materially reducing one source of potential equity dilution from its convertible bond while simultaneously creating a sizeable new pool of long-term management equity incentives as several important oncology catalysts approach.

Avacta’s shares were trading around 67.5 pence on September 7, slightly below the option exercise price and broadly unchanged from the 68 pence level at the start of the month. The company’s market capitalization was approximately £316 million, making the remaining £12 million bond principal equivalent to around 3.8% of equity value, consistent with Avacta’s own calculation. The stock remained inside a 52-week range of roughly 48 pence to 92 pence, with no clear evidence that investors have treated either the cash bond repayment or management option grant as a decisive valuation event by itself.

Why did Avacta choose to pay another £2.61 million bond installment in cash instead of shares?

The latest payment relates to the April 2026 quarterly installment that had previously been deferred under amendments agreed with the convertible bond holder. After receiving an accelerated payment notice, Avacta elected to settle £2.613 million in cash, comprising £2.4 million of principal together with interest and fees associated with the deferment.

That decision is consistent with the financing strategy Avacta laid out in June. The company secured approximately £9 million through an equity placing at 70 pence per share specifically to fund convertible bond repayments. Avacta argued at the time that issuing new equity at 70 pence was preferable to potentially satisfying deferred bond installments in shares at much lower reference prices.

The potential share-settlement reference prices for the January and April deferred installments could have been as low as approximately 48.75 pence and 64.65 pence respectively. Raising equity at 70 pence and then paying the bond in cash therefore allowed Avacta to reduce the number of shares potentially issued to satisfy the debt.

That does not mean the strategy eliminated dilution. The June placing itself created 12.79 million new shares, while director subscriptions added a small additional amount. The distinction is that Avacta chose the timing and price of that equity issuance rather than allowing the bond repayment formula to determine the number of shares delivered to the creditor.

How quickly has Avacta reduced the original £55 million convertible bond?

The remaining balance is substantially smaller than the financing Avacta originally took on. The company issued £55 million of senior unsecured convertible bonds in October 2022, receiving approximately £52.25 million of proceeds after the bonds were issued at 95% of par.

The bonds carry a 6.5% fixed coupon and were structured with quarterly principal and interest repayments. Avacta subsequently amended the terms several times as it balanced clinical-development spending, cash runway and shareholder dilution.

After the accelerated January deferred payment was settled in July 2026, the remaining principal fell to £16.8 million. The scheduled July repayment then reduced principal by another £2.4 million, while the newly accelerated April installment removed a further £2.4 million, bringing the balance to £12 million.

Avacta has therefore reduced principal by £43 million from the original £55 million, or approximately 78%. That substantially diminishes the convertible bond’s importance relative to the company’s capital structure, although £12 million remains meaningful for a clinical-stage biotechnology company that is not yet generating commercial drug revenue.

Cash rather than bond principal now becomes the more important financing variable. Every cash repayment removes future debt and potential share issuance but also uses resources that might otherwise support clinical trials, regulatory work or pipeline expansion.

Does Avacta still have enough cash to reach its next major clinical milestones?

Avacta reported £16.4 million of cash at April 30, 2026 after completing a £10 million equity financing in March. Management said that financing extended its operating cash runway into early Q1 2027 and beyond the initial clinical readout from AVA6103 expected in late 2026.

The subsequent £9 million June placing was structured primarily around bond reduction rather than extending the core research and development runway. Since then, Avacta has paid the £3.67 million accelerated January installment, the scheduled July bond payment and the latest £2.613 million accelerated April payment.

The company has not published a current September cash balance, so subtracting those payments from April cash would produce a misleading estimate. Avacta has continued spending on clinical trials, research and normal operations while also receiving the June financing proceeds.

The more defensible conclusion is that management continues to guide toward the previously identified clinical milestones while deliberately reducing debt. The next financing question will become clearer after the late-2026 AVA6103 readout and as Avacta determines the development path for its other pre|CISION assets.

Partnering could alter that equation materially. Avacta continues to say it is in discussions with multiple potential partners across its first-, second- and third-generation programs. A licensing or co-development agreement containing meaningful upfront economics could provide non-equity capital, while an absence of partnering proceeds would leave the company more dependent on its existing cash and capital-market access.

How large are the 19.15 million management options relative to Avacta’s existing shareholders?

The new award comprises 13.4 million options for Christina Coughlin, 2 million for chief financial officer Brian Hahn and another 3.75 million distributed among the rest of the management team. In total, the grant covers 19.15 million shares.

Avacta currently has roughly 471 million shares outstanding. The new option pool is therefore equivalent to approximately 4.1% of current issued share capital. Actual dilution does not occur immediately because the options must first vest and subsequently be exercised.

If every new option were ultimately exercised at 69 pence, Avacta would receive approximately £13.2 million of exercise proceeds. The resulting increase in total shares would dilute existing holders by about 3.9% on a post-exercise basis before considering any other future equity issuance.

The options are currently slightly out of the money with Avacta shares around 67.5 pence. Their economic value becomes much more significant only if the share price rises above 69 pence and the relevant vesting requirements are achieved.

Coughlin’s total option position after the award is 17 million shares, equivalent to 3.61% of Avacta’s current issued share capital. Hahn holds options over 4.1 million shares, representing approximately 0.87%.

Why are half of Christina Coughlin’s new options tied to clinical milestones rather than time alone?

Of Coughlin’s 13.4 million new options, 6.7 million vest over four years based on continued service. Four equal tranches of 1.675 million options are scheduled to vest annually between August 2027 and August 2030.

The remaining 6.7 million are linked to three operational milestones. Approximately 2.23 million vest following presentation of Phase 1 AVA6103 data, another 2.23 million are tied to filing the next Investigational New Drug application, and the final approximately 2.23 million depend on clinical candidate selection for Avacta’s next-generation asset.

Those conditions align management incentives directly with events that could expand the value of the pre|CISION platform. They are also relatively concrete milestones that investors can monitor rather than broad discretionary performance assessments.

There is an important limitation, however. The conditions focus on development execution rather than clinical success, regulatory approval, partnering economics or shareholder return. Presenting Phase 1 data, filing an IND or selecting a candidate does not guarantee that the corresponding drug ultimately demonstrates sufficient efficacy or commercial value.

The options therefore reward management for advancing the pipeline into value-generating stages rather than requiring those programs ultimately to succeed. Avacta said it took advice from Aon’s Talent Solutions team when structuring the awards, while Coughlin’s notice period has also been extended to 12 months.

Why does AVA6103 make the option award particularly sensitive for Avacta shareholders?

AVA6103 has become one of the most important near-term tests of Avacta’s underlying technology. The molecule is the company’s second-generation pre|CISION candidate and is designed to deliver exatecan selectively into tumors through a sustained-release mechanism.

The first patient was treated in the FOCUS-01 Phase 1 study in March 2026. Initial clinical data remain expected in late 2026, meaning the first performance-linked tranche of Coughlin’s options is tied to a milestone investors were already treating as a major valuation catalyst.

Preclinical studies have suggested prolonged tumor exposure and limited systemic exposure, but the clinical study now needs to demonstrate how those properties translate in patients. Initial Phase 1 data will primarily address pharmacology, safety, payload release and preliminary efficacy rather than establish definitive clinical benefit.

Avacta’s first-generation program, faridoxorubicin or AVA6000, has already provided some clinical evidence supporting the broader pre|CISION mechanism. Updated data presented in June showed responses in salivary gland cancer, while the U.S. Food and Drug Administration agreed with Avacta on a potential single pivotal trial using progression-free survival as the primary endpoint.

Avacta has nevertheless said it intends to advance faridoxorubicin into pivotal development only with a partner. That leaves AVA6103 increasingly central to proving that pre|CISION can work across multiple payloads rather than being judged through a single doxorubicin program.

Does reducing the convertible bond meaningfully lower future dilution risk?

Yes, but it does not eliminate financing risk.

The amended bond still allows the holder certain conversion and acceleration rights. Its conversion price was reset to 75 pence under the 2025 amendments, although share settlement of amortization installments can use separate calculations linked to prevailing market prices.

Reducing principal from £55 million to £12 million therefore materially shrinks the amount capable of generating future bond-related equity issuance. At the current approximately £316 million market capitalization, the remaining principal represents less than 4% of Avacta’s equity value.

That is a much more manageable capital-structure burden than the original bond. The trade-off is that Avacta has partly achieved the reduction by selling equity directly and using the proceeds for cash repayment. Shareholders have still experienced dilution, but the company has sought to execute it at controlled prices.

The management option award introduces a different type of potential dilution. Unlike bond settlement, the options would bring cash into Avacta if exercised and generally require a higher share price to become economically attractive. They also vest over several years or depend on R&D milestones, so they are not equivalent to an immediate share issuance.

Investors should therefore avoid simply adding the 19.15 million options to the £12 million bond and treating both as identical dilution. One represents remaining financial debt with conversion features; the other represents long-term employee incentives that become shares only after vesting and exercise.

What does Avacta’s share price say about investor reaction to the bond payment and option grants?

Avacta traded around 67.5 pence during September 7, compared with 68 pence on September 1 when the management option award was announced. That leaves the stock broadly unchanged across the two announcements rather than showing an obvious negative reaction.

The shares closed at 67.5 pence on September 4, the day of the accelerated bond-payment announcement, after rising approximately 2.3% from the previous session. The move should not automatically be attributed to the repayment because small-cap biotechnology shares can move substantially on relatively modest trading volumes and broader investor positioning.

Across roughly one month, the stock has also been broadly flat, trading around 67 pence in early August. The wider 52-week range of approximately 48 pence to 92 pence shows considerably greater volatility than the recent announcements have generated.

That relative stability may indicate that investors increasingly see bond reduction as an expected part of the financing plan rather than a new development requiring major repricing. The management options likewise matter for future dilution and governance, but their value depends substantially on the company delivering the clinical milestones shareholders are already waiting for.

What will determine whether Avacta’s financing strategy creates more value than dilution?

The next decisive evidence comes from the pipeline rather than another debt notice. Initial AVA6103 clinical data expected later in 2026 need to show that the second-generation pre|CISION technology behaves in patients in a way consistent with Avacta’s preclinical rationale.

Partnering is the second major test. Avacta has deliberately retained full ownership of AVA6103 through the initial clinical readout while continuing discussions around several programs. A commercial agreement providing meaningful upfront cash could reduce reliance on further equity financing and validate external interest in the platform.

The third measurement is the remaining bond balance. Reducing principal from £55 million to £12 million is substantial progress, but the final £12 million still needs to be serviced while clinical-development expenditure continues.

Management incentives then sit on top of those financial milestones. The 19.15 million new options are large enough to matter to shareholders, but roughly half of Coughlin’s award is explicitly tied to advancing the pipeline. If those milestones create significantly more enterprise value than the resulting dilution, the incentive structure can work as intended.

Avacta has therefore reached a cleaner but not yet self-funding stage of its capital structure. The convertible bond is now less than one-quarter of its original size, two deferred repayments have been removed in cash and the company has avoided potentially more dilutive share settlement at lower reference prices. The remaining question is whether the clinical progress management is being incentivized to deliver can arrive fast enough to make future financing increasingly dependent on drug value rather than repeated equity issuance.

What are the key takeaways from Avacta’s bond repayment and management option awards?

• Avacta paid £2.613 million in cash to satisfy the accelerated April 2026 deferred convertible bond installment.
• The payment included £2.4 million of principal plus associated interest and deferment fees.
• After the latest payment and the scheduled July installment, remaining convertible bond principal has fallen to £12 million.
• Avacta originally issued £55 million of convertible bonds in 2022, meaning approximately 78% of the original principal has now been repaid.
• Avacta raised approximately £9 million at 70 pence per share in June specifically to support cash repayment of the bond and reduce potential dilution.
• Management received 19.15 million new options at a 69-pence exercise price, equivalent to about 4.1% of existing issued capital.
• CEO Christina Coughlin received 13.4 million options, half of which are linked to AVA6103 data, another IND filing and next-generation candidate selection.
• If all 19.15 million new options eventually vest and are exercised, Avacta would receive approximately £13.2 million of exercise proceeds.
• Avacta previously guided to an operating cash runway into early Q1 2027, while initial AVA6103 Phase 1 data remain expected in late 2026.
• Avacta shares remain broadly unchanged around 67.5 pence across the recent option and bond announcements, with a 52-week range of approximately 48 pence to 92 pence.